Loading…
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $829M | $165M | $-2M | $157M | -0.3% | 23258.2% | - |
| 2024 | $4M | $-562M | $-599M | $-604M | -313.8% | -98.5% | - |
| 2023 | $241M | $-176M | $-205M | $-331M | -71.5% | -1.0% | - |
| 2022 | $243M | $-162M | $-176M | $-189M | -42.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 243.23 | 240.74 | 3.55 | 829.45 |
| Operating Expense | 421.74 | 445.74 | 604.63 | 731.10 |
| Operating Income | -178.51 | -205 | -601.08 | 98.35 |
| EBITDA | -162.29 | -175.67 | -561.51 | 164.82 |
| EBIT | -172.71 | -188.16 | -580.11 | 140.89 |
| Pretax Income | -172.71 | -206.49 | -612.46 | 51.53 |
| Tax Provision | 3.79 | 2.78 | -2.77 | 21.42 |
| Net Income | -176.06 | -205.28 | -599.49 | -1.63 |
| Net Income Common Stockholders | -176.06 | -205.28 | -599.49 | -1.63 |
| Total Expenses | 421.74 | 445.74 | 604.63 | 731.10 |
| Interest Expense | 0 | 18.33 | 32.35 | 89.36 |
| Interest Income | 5.03 | 15.30 | 22.72 | 37.29 |
| Research And Development | 297.31 | 353.19 | 505.87 | 607.16 |
| Selling General And Administration | 124.43 | 90.93 | 96.82 | 121.92 |
| Normalized EBITDA | -162.29 | -175.67 | -561.51 | 164.82 |
| Normalized Income | -176.06 | -205.28 | -599.49 | -1.63 |
| Basic EPS | -1.63 | -1.91 | -5 | -0.01 |
| Diluted EPS | -1.67 | -1.92 | -5 | -0.01 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.01 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -176.06 | -205.28 | -599.49 | -1.63 |
| Reconciled Depreciation | 10.42 | 12.49 | 18.59 | 23.93 |
| Net Interest Income | 5.03 | -3.03 | -9.63 | -52.07 |
| Net Income From Continuing And Discontinued Operation | -176.06 | -205.28 | -599.49 | -1.63 |
| Total Operating Income As Reported | -178.51 | -205 | -601.08 | 98.35 |
| Diluted Average Shares | 105.96 | 107.31 | 119.78 | 133.76 |
| Basic Average Shares | 105.96 | 107.31 | 119.78 | 133.76 |
| Diluted NI Availto Com Stockholders | -176.06 | -205.28 | -599.49 | -1.63 |
| Minority Interests | 0.43 | 4 | 10.20 | -31.75 |
| Net Income Including Noncontrolling Interests | -176.49 | -209.28 | -609.69 | 30.11 |
| Net Income Continuous Operations | -176.49 | -209.28 | -609.69 | 30.11 |
| Other Income Expense | 0.77 | 1.54 | -1.75 | 5.26 |
| Other Non Operating Income Expenses | 0.77 | 1.54 | -1.75 | 5.26 |
| Net Non Operating Interest Income Expense | 5.03 | -3.03 | -9.63 | -52.07 |
| Total Other Finance Cost | -5.03 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0 | 18.33 | 32.35 | 89.36 |
| Interest Income Non Operating | 5.03 | 15.30 | 22.72 | 37.29 |
| Depreciation Amortization Depletion Income Statement | 1.61 | 1.62 | 1.94 | 2.03 |
| Depreciation And Amortization In Income Statement | 1.61 | 1.62 | 1.94 | 2.03 |
| General And Administrative Expense | 124.43 | 90.93 | 96.82 | 121.92 |
| Other Gand A | 124.43 | 24.14 | 28.85 | 59.21 |
| Salaries And Wages | 105.17 | 66.80 | 67.97 | 62.70 |
| Operating Revenue | 243.23 | 240.74 | 3.55 | 829.45 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc.this co. | ARWR | - | - | - | -0.3% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |